The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia
- PMID: 36246525
- PMCID: PMC9556631
- DOI: 10.3389/fncel.2022.1024649
The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia
Abstract
Schizophrenia is a severe mental disorder characterized by positive, negative, and cognitive symptoms. Cognitive symptoms are a kind of symptoms with high incidence and great impact on patients. There is no effective treatment in clinical practice. N-methyl-d-aspartic acid (NMDA) receptor hypofunction may be an important cause of cognitive symptoms. MK-801 (also named Dizocilpine), a noncompetitive antagonist of NMDA receptor, is often used to construct a model of NMDA receptor dysfunction. In terms of treatment, environmental enrichment (EE) as an environmental intervention can effectively improve the symptoms of cognitive impairment in rodents. In this paper, we first briefly introduce the background of cognitive symptoms and EE in schizophrenia, and then investigate the manifestations of MK-801 induced cognitive impairment, the improvement of EE on these cognitive impairments based on the MK-801 induced schizophrenia rodent models, and the possible mechanism of EE in improving cognitive symptoms. This article reviews the literature in recent years, which provides an important reference for MK-801 to construct a cognitive symptom model of schizophrenia and the mechanism of EE in improving cognitive symptoms of schizophrenia.
Keywords: MK-801; cognitive symptoms; environmental enrichment; mechanism; schizophrenia.
Copyright © 2022 Xu, Li, Tian, Liu, Wu and Wang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: an animal model for cognitive symptoms of schizophrenia.J Physiol Paris. 2013 Dec;107(6):448-51. doi: 10.1016/j.jphysparis.2013.04.003. Epub 2013 Apr 18. J Physiol Paris. 2013. PMID: 23603055 Review.
-
Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Mar 3;49:53-62. doi: 10.1016/j.pnpbp.2013.11.008. Epub 2013 Nov 19. Prog Neuropsychopharmacol Biol Psychiatry. 2014. PMID: 24269664
-
Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model.Eur Neuropsychopharmacol. 2019 May;29(5):590-600. doi: 10.1016/j.euroneuro.2019.03.009. Epub 2019 Mar 26. Eur Neuropsychopharmacol. 2019. PMID: 30926324
-
Selective impairment of timing in a NMDA hypofunction animal model of psychosis.Behav Brain Res. 2022 Feb 15;419:113671. doi: 10.1016/j.bbr.2021.113671. Epub 2021 Nov 14. Behav Brain Res. 2022. PMID: 34788697
-
Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.Int J Neuropsychopharmacol. 2013 Nov;16(10):2181-94. doi: 10.1017/S1461145713000928. Int J Neuropsychopharmacol. 2013. PMID: 24099265 Review.
Cited by
-
Theta-frequency medial septal nucleus deep brain stimulation increases neurovascular activity in MK-801-treated mice.Front Neurosci. 2024 Mar 15;18:1372315. doi: 10.3389/fnins.2024.1372315. eCollection 2024. Front Neurosci. 2024. PMID: 38560047 Free PMC article.
-
Effects of Nicotine Administration in an Enriched Environment on the Behavior of Male MK-801-Exposed Rats.Addict Health. 2023 Oct;15(4):260-265. doi: 10.34172/ahj.2023.1433. Epub 2023 Oct 29. Addict Health. 2023. PMID: 38322486 Free PMC article.
-
SHANK3 Mutations Associated with Autism and Schizophrenia Lead to Shared and Distinct Changes in Dendritic Spine Dynamics in the Developing Mouse Brain.Neuroscience. 2023 Sep 15;528:1-11. doi: 10.1016/j.neuroscience.2023.07.024. Epub 2023 Jul 31. Neuroscience. 2023. PMID: 37532012 Free PMC article.
-
Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia.Front Pharmacol. 2024 Jan 24;15:1298061. doi: 10.3389/fphar.2024.1298061. eCollection 2024. Front Pharmacol. 2024. PMID: 38327987 Free PMC article.
-
Automated Behavioral Analysis of Schizophrenia-like Phenotypes in Repeated MK-801-Treated Mice Using IntelliCage.Int J Mol Sci. 2025 May 28;26(11):5184. doi: 10.3390/ijms26115184. Int J Mol Sci. 2025. PMID: 40508003 Free PMC article.
References
-
- Batinic B. (2019). Cognitive models of positive and negative symptoms of schizophrenia and implications for treatment. Psychiatr. Danub. 31, 181–184. - PubMed
Publication types
LinkOut - more resources
Full Text Sources